Virginia has passed legislation permitting the substitution of biosimiliar drugs for brand-name biologics -- but with restrictive conditions. Similar legislation has passed or is pending in several other states, and a key point in the bills is the requirement that the FDA certify that a biosimilar is interchangeable with the prescribed biologic medication.

Full Story:

Related Summaries